solute carrier family 35 member D2Genealiases: HFRC1 · SQV7L · UGTrel8 · hfrc
Q-omics provides the consensus-scored SLC35D2 profile across patient tissues and cancer cell-line models. SLC35D2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC35D2 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, SLC35D2 RNA expression shows 19,707 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where SLC35D2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC35D2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC35D2 survival associations across molecular data types. SLC35D2 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC35D2 RNA expression–survival associations across cancer types. High SLC35D2 expression shows unfavorable associations in UCS, ACC, LGG, HNSC and LIHC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC35D2 RNA expression.
This table summarizes SLC35D2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SLC35D2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC35D2 shows lower tumor expression in THCA, KICH and COAD and higher tumor expression in HNSC, LIHC and STAD. The THCA box plot shows higher SLC35D2 RNA expression in normal versus tumor tissue (log2 FC = −1.040, t-test p < 0.001).
This table shows molecular features associated with SLC35D2 in patient tissues and cancer cell lines. In patient samples, SLC35D2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC35D2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BONE.
